Our results suggest that EGLN1 inhibition may be a means to more selectively shift the balance between OXPHOS and glycolysis in tRCC cells. The gene discussed is EGLN1; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.